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Abstract
Introduction:  Blood  component  wastage  has  become  a  ﬁnancial  and  ethical  challenge  in  every-
day hospital  practice.  Inadequate  indication  of  blood  products  has  been  reported  in  up  to  57.3%
of cases.  This  has  caused  a  signiﬁcant  increase  in  the  costs  associated  with  blood  transfusion.
The aim  of  this  study  was  to  establish  the  impact  of  inadequate  indication  of  blood  products
on costs  related  to  blood  transfusion  in  a  university  hospital.
Material  and  methods:  A  retrospective,  descriptive,  observational  study  was  conducted  to
evaluate blood  product  transfusions  performed  between  January  1  and  June  30,  2015,  based  on
the criteria  of  the  American  Association  of  Blood  Banks.  The  direct  cost  of  blood  product  units
was determined  and  transfusions  were  classiﬁed  by  type  of  indication,  and  the  service  ordering
the transfusion.
Results:  Based  on  the  American  Association  of  Blood  Banks  guidelines,  1028  transfusions  were
evaluated  and  47.8%  of  these  had  an  inadequate  indication,  equivalent  to  an  estimated
$38,766.87  USD  for  direct  processing  costs.  According  to  the  type  of  blood  product  trans-
fused, 29.4%  of  fresh  frozen  plasma,  38.6%  of  packed  red  blood  cells,  and  68.2%  of  platelet
concentrates  had  an  inadequate  indication.
Conclusions:  An  inadequate  blood  transfusion  indication  produces  a  high  impact  on  costs  related
to blood  transfusion  involving  an  estimated  yearly  unnecessary  expense  of  $860,766.64  USD  in
our hospital.
©  2016  Universidad  Auto´noma  de  Nuevo  Leo´n.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is
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reventive  strategies  are  needed  for  the  identiﬁcation,  eval-
ation  and  treatment  of  anemia,  to  optimizing  hemostasis
nd  to  establish  decision  thresholds  to  minimize  inadequate
se  of  blood  and  its  products.1 According  to  the  American
ssociation  of  Blood  Banks  (AABB),  approximately  15  million
nits  of  packed  red  blood  cells  (RBC)  are  transfused  in  the
nited  States  and  almost  85  million  are  transfused  annually
orldwide.2 In  2013,  the  National  Blood  Transfusion  Center
n  Mexico  (CNTS,  in  Spanish)  reported  that  5,933,405  units
ere  dispensed;  however,  to  date  the  total  number  of  units
ransfused  at  the  national  level  has  not  been  published.3
In  the  state  of  Nuevo  Leon,  in  2014,  a  total  of  235,935
nits4 were  dispensed;  of  these,  according  to  reports  from
he  State  Center  for  Blood  Transfusion  (CETS),  162,340
68.8%)  were  transfused.5 At  the  University  Hospital  of
he  Autonomous  University  of  Nuevo  Leon  (HU-UANL)  dur-
ng  2014,  a  total  of  22,808  units  of  blood  products  were
ransfused.6
The  AABB  has  published  guidelines  that  establish  the  dif-
erent  criteria  for  transfusing  fresh  frozen  plasma  (FFP),7
BC,  and  platelet  concentrates  (PC).8 In  2007,  The  Mexican
ssociation  of  Transfusion  Medicine  (AMMTAC,  in  Spanish)
ublished  the  Guidelines  for  the  Clinical  Use  of  Blood,which
rovides  clinical  and  laboratory  criteria  for  the  use  of  blood
nd  blood  products.9
According  to  the  literature  0.3--57.3%  of  transfusions  are
nadequate.10 Regarding  the  type  of  blood  product  trans-
used,  for  RBC,  up  to  70%  of  transfusions  are  inadequate,
hile  for  FFP  it  has  reached  87.5%.11 Nationally,  the  percent-
ge  of  inadequate  transfusions  reached  45%.12 According  to
 study  by  González-Villanueva  et  al.  performed  from  2009
o  2011  in  patients  from  the  Internal  Medicine,  Orthope-
ics,  Gynecology  and  Surgery  Services  of  ‘‘Dr.  José  Eleuterio
onzález’’  University  Hospital,  in  Monterrey,  Mexico,  16.2%
f  transfusion  were  inadequate  based  on  AMMTAC  criteria.10
owever,  the  percentage  of  inadequate  transfusions  in  other
reas  of  this  hospital  is  unknown.
The  use  of  methods  for  risk  reduction  and  the  develop-
ent  and  implementation  of  new  technologies  for  donation
nd  transfusion  have  contributed  to  a  signiﬁcant  increase  in
he  cost  of  blood  transfusion.13 Currently,  1%  of  total  hospi-
al  costs  are  attributed  to  blood  transfusion;  however,  this
ay  vary  by  disease  and  procedure.  For  example,  in  treat-
ents  such  as  liver  and  bone  marrow  transplants,  blood
ransfusion  plays  an  important  ﬁnancial  role  representing
%  to  9%  of  total  hospital  costs,  which  can  easily  exceed
3800  USD  per  treatment.14 A  study  published  by  Sanchez-
lvarez  et  al.  in  2000,  reported  a  RBC  unit  cost  of  $1750
XN  (equivalent  to  $98.59  USD)  in  a  public  hospital,  while
n  a  private  hospital  the  cost  was  $5232.25  MXN,  (equivalent
o  $294.77  USD),  thus  establishing  a  signiﬁcant  difference  in
osts  related  to  transfusion  in  the  public  versus  the  private
ector.15
In  2004,  Juarez-Rangel  et  al.  published  a  retrospective
tudy  from  the  CNTS,  which  reported  that  up  to  63.3%  of
lood  products  were  inadequately  transfused,  with  an  esti-Please  cite  this  article  in  press  as:  Cázares-Benito  MA,  et  al.  I
transfusion.  Medicina  Universitaria.  2016.  http://dx.doi.org/1
ated  impact  of  $1,700,000.00  MXN,  equivalent  to  about
95,775  USD,  annually  in  direct  costs.12
Numerous  studies  have  established  the  beneﬁts  of  imple-
enting  restrictive  transfusion  strategies.2,16--20 Since  these
R
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trategies  are  currently  being  implemented  in  our  hospi-
al,  we  considered  it  important  to  assess  proper  adherence
o  international  guidelines  (AABB)  and  its  impact  on  costs
elated  to  blood  transfusion.
aterial and methods
his  is  a retrospective,  observational,  descriptive  study  of
ransfusion  of  blood  products  (RBC,  FFP  and  PC)  performed
t  the  ‘‘Dr.  José  Eleuterio  González’’  University  Hospital  in
onterrey,  Mexico,  from  January  1  to  June  30,  2015.  The
tudy  was  based  on  the  number  of  blood  products  trans-
used,  registered  in  the  CiBank  blood  bank  hospital  system
uring  2014.  Using  the  formula  for  calculating  proportions
n  ﬁnite  populations  with  an  expected  rate  of  50%,  an  accu-
acy  of  0.03  and  a conﬁdence  interval  of  95%,  we  obtained
 sample  size  of  1019  transfusions.  In  order  to  project  with
reater  adherence  the  hospital’s  transfusion  behavior,  the
ample  was  randomly  distributed  over  a period  of  6  months
sing  Epidat  version  4.1.
Transfusions  of  RBC,  FFP  and  PC  in  hospitalized  patients
lder  than  18  years  were  included.
Transfusions  in  pediatric  patients  were  not  included
n  this  study,  since  the  indication  for  transfusion  in
hese  patients  includes  different  criteria  for  transfusion  of
lood  components  in  adults,  cryoprecipitate  transfusions
ere  not  included  because  of  the  special  requirements
or  transfusion,  apheresis  platelet  transfusions  were  not
ncluded,  because  in  our  hospital  they  are  performed  under
he  express  request  of  the  treating  physician  and  pre-
rogramming  of  the  procedure;  records  with  incomplete
ata  were  excluded.
The  medical  record  of  each  patient  was  reviewed  and
he  presence  of  acute  bleeding  was  assessed  according  to
he  classiﬁcation  of  the  AMMTAC.9 The  indication  of  trans-
usion  of  blood  products  was  evaluated  according  to  the
ecommendations  of  the  AABB.2,7,8
For  cost  analysis,  an  estimate  was  made  considering  costs
irectly  related  (resources)  to  the  processing  of  units  (blood
onor  selection,  collection,  analysis,  fractionation,  stor-
ge,  and  compatibility  testing)  according  to  current  market
rices  without  considering  the  annual  inﬂation  rate.  Costs
ere  pooled  by  units  transfused  in  each  service  and  costs
er  unit  transfused  with  an  inadequate  indication.  Conver-
ion  of  Mexican  pesos  (MXN)  to  United  States  dollars  (USD)
as  performed  according  to  the  Exchange  Rate  to  Settle
iabilities  Denominated  in  United  States  Dollars  Payable  in
exico,  published  by  the  Bank  of  Mexico  on  March  7,  2016.
Statistical  analysis  was  performed  using  SPSS  version  20.0
or  Windows;  for  categorical  variables  frequency  and  per-
entage  tables  were  used  and  bar  and  sectors  graphs  were
reated.  For  numeric  variables,  measures  of  central  ten-
ency  and  location,  such  as  median  and  interquartile  ranges
as  used.  Pearson’s  Chi  square  test  was  used  for  compar-
son  of  categorical  variables,  considering  a  value  ≤.05  as
tatistically  signiﬁcant.mpact  on  costs  related  to  inadequate  indication  of  blood
0.1016/j.rmu.2016.07.003
esults
n  total,  1447  units  of  blood  products  transfused  between
anuary  1  and  June  30,  2015  were  selected  for  analysis.  Of
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Table  1  Inadequate  indication  of  blood  product  transfusion  by  medical  service  at  the  ‘‘Dr.  José  Eleuterio  González’’  University
Hospital, Monterrey,  México,  from  January  to  June,  2015.
Service  Blood  product  transfused
Inadequate  Indication  Total
RBC  FFP  PC
n (%)  n  (%)  n  (%)  n  (%)  n  (%)
Surgery  25  (65.8)  13  (52)  0  (0)  12  (100)  38  (3.7)
Plastic surgery 2(40) 2  (40)  0  (0)  0  (0)  5  (0.5)
Gynecology 14  (29.8) 9  (21.4) 1  (100)  4  (100)  47  (4.6)
Internal medicine 123  (44.1) 21  (24.1) 8  (28.6) 94  (57.3) 279  (27.1)
Neurosurgery  3  (60) 3  (60) 0  (0) 0  (0) 5  (0.5)
Neurology 4  (40)  0  (0)  0  (0)  4  (80)  10  (1.0)
Obstetrics 7  (70)  2  (40)  2  (100)  3  (100)  10  (1.0)
Oncology 1  (20)  1  (20)  0  (0)  0  (0)  5  (0.5)
Otolaryngology  1  (100)  1  (100)  0  (0)  0  (0)  1  (0.1)
University empolyee  medical  services  13  (20.6)  7  (21.9)  0  (0)  6  (21.4)  63  (6.1)
Post-surgical  7  (58.3)  2  (40)  2  (50)  3  (100)  12  (1.2)
Operating room  140  (72.9)  89  (67.4)  9  (50)  42  (100)  192  (18.7)
Delivery 8  (47.1)  6  (60)  0  (0)  2  (33.3)  17  (1.7)
Traumatology  8  (66.7)  8  (66.7)  0  (0)  0  (0)  12  (1.2)
Adult ICU  29  (43.3)  3  (16.7)  7  (25.9)  19  (86.4)  67  (6.5)
Post-surgical  ICU  43  (41.3)  2  (9.1)  8  (21.1)  33  (75)  104  (10.1)
Renal unit  0(0)  0  (0)  0  (0)  0  (0)  4  (0.4)
Adult ER  63  (40.1)  28  (29.5)  8  (26.7)  27  (84.4)  157  (15.3)
Total 491 (47.8)  197  (38.6)  45  (29.4)  249  (68.2)  1028  (100)
Table  2  Processing  cost  per  unit,  in  USD,  at  the  ‘‘Dr.  José
Eleuterio  González’’  University  Hospital,  Monterrey,  México.
Concept  USD
Donor  evaluation  $7.70
Donation  $11.92
Serology  $41.35
Pre-transfusion  tests $17.07
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$ER, emergency room.
these,  419  were  excluded  for  not  meeting  inclusion  criteria,
leaving  a  total  of  1028  transfusions.
The  highest  number  of  transfusions  were  recorded  in
Internal  Medicine,  the  Operating  Room  and  the  Adult  Emer-
gency  Room  with  279  (27.1%),  192  (18.7%)  and  157  (15.3%)
units  transfused,  respectively,  while  the  services  with  the
lowest  number  of  transfusions  were  Plastic  Surgery,  Oncol-
ogy,  the  Renal  Unit,  and  Otolaryngology,  which  comprised
1.5%  of  the  units  included  in  this  study.
Evaluation  of  the  indication  of  transfusion  of  blood  prod-
ucts,  based  on  the  guidelines  of  the  AABB,  showed  that  47.8%
of  the  transfusions  were  inadequate.  Among  the  services
with  the  greatest  number  of  transfusions,  the  highest  per-
centage  of  inadequate  indications  occurred  in  the  Operating
Room  (72.9%),  while  in  Internal  Medicine  and  the  Adult  ER
it  was  44.1%  and  40.1%,  respectively.
Regarding  the  type  of  units  transfused  510  (49.6%)  were
RBC,  365  (35.5%)  were  PC  and  153  (14.9%)  were  FFP.PCs  had
the  highest  percentage  of  inadequate  transfusions  (68.2%),
compared  to  RBC  and  FFP  (Table  1).
A  statistically  signiﬁcant  difference  was  found  when  the
service  and  the  indication  for  RBC  and  PC  transfusion  were
compared  (P  ≤  .001),  however,  this  did  not  occur  with  FFP
(P  =  .120).
To  conduct  a  cost  analysis  and  evaluation  of  the  impact  of
inadequate  transfusion  of  blood  products,  the  approximatePlease  cite  this  article  in  press  as:  Cázares-Benito  MA,  et  al.  I
transfusion.  Medicina  Universitaria.  2016.  http://dx.doi.org/10
amount  of  processing  a  unit  of  blood  was  calculated  at  a
direct  cost  of  $78.96  USD  per  unit  collected  (Table  2).
Based  on  the  results,  the  estimated  cost  for  processing
the  1028  units  included  in  this  study  was  $81,165.67  USD,  of
D
T
oOther  $0.91
Cost per  unit  $78.96
hich  $38,766.87  USD  correspond  to  491  units  transfused
ith  an  inadequate  indication  according  to  AABB  crite-
ia.  Extrapolating  the  results  of  this  study  at  the  hospital
evel,  a  one-year  total  of  $860,766.64  USD  would  have  been
xpended  in  the  inadequate  transfusion  of  10,902  units.
t  the  state  level,  this  would  represent  a  total  of  77,599
nits  transfused  with  an  inadequate  indication,  with  an  esti-
ated  cost  of  $6,126,823.58  USD.  While  at  the  national
evel,  inferring  that  the  rate  of  national  transfusion  in  2013
as  the  same  as  that  of  the  state  in  2014  (68.8%),  approxi-
ately  1,951,283  units  would  have  been  transfused  with  an
nadequate  indication,  representing  a  cost  of  approximately
154,063,411.85  USD  in  2013.mpact  on  costs  related  to  inadequate  indication  of  blood
.1016/j.rmu.2016.07.003
iscussion
he  main  objective  of  this  study  was  to  establish  the  impact
f  inadequate  indication  of  blood  products  on  costs  related
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o  blood  transfusion.  Based  on  the  guidelines  of  the  AABB,
e  found  that  47.8%  of  the  transfusion  of  blood  products
ad  an  inadequate  indication;  this  places  the  behavior  of
ur  hospital’s  transfusions  within  percentages  reported  both
ationally  and  internationally.10,11
A  previous  study  published  by  Gonzalez-Villanueva
t  al.10 found  that  16.2%  of  the  transfusions  in  our  hospital
ere  inadequate.  Our  report  shows  approximately  a  3-fold
ncrease  in  the  percentage  of  inadequate  transfusions;  how-
ver,  in  the  previous  study  only  Internal  Medicine,  General
urgery,  Gynecology  and  Obstetrics,  and  Orthopedics  were
valuated,  while  our  study  covered  services  more  involved
n  transfusion  practice  such  as  the  Adult  Emergency  Room,
he  intensive  care  unit,  the  operating  room,  and  the  renal
nit.
Similarly,  this  increase  in  inadequate  indications  may
e  because  the  AABB  guidelines  have  more  restrictive  ﬁg-
res  for  transfusion  of  blood  products,  primarily  for  RBC,
here  hemoglobin  levels  of  7.0--8.0  g/dLare  used  in  stable
atients.2 National  guidelines  (AMMTAC)  indicate  transfu-
ion  of  RBC  in  ‘‘anemia  with  signs  and  symptoms  of  tissue
ypoxia  in  normovolemic  patients,  regardless  of  hemoglobin
evels’’.9
With  regard  to  service  indicating  transfusion,  internal
edicine  had  the  highest  number  of  units  transfused  with
 total  of  279  (27.1%),  followed  by  the  operating  rooms  with
 total  of  192  units.  According  to  the  type  of  indication,  we
bserved  that  surgical  areas  had  the  highest  percentages
f  inadequate  indication  compared  to  nonsurgical  services.
his  strongly  correlates  with  that  reported  by  González-
illanueva  in  2012.10
The  literature  has  reported  up  to  74%  of  inadequate  indi-
ations  for  RBC  and  96.2%  for  FFP,11 while  for  PC,  up  to  13%
f  inadequate  transfusions  have  been  reported.12 This  places
he  results  of  this  study  in  a  good  position  with  regard  to
ransfusion  of  RBC  and  FFP,  but  not  in  transfusion  of  PC.
A  cost  per  unit  transfused  ranging  from  $118.42  USD21 to
1183  USD  has  been  reported  in  the  literature.22 The  esti-
ated  cost  per  unit  of  transfused  blood  products  in  this
tudy  was  $78.96  USD,  which  was  slightly  less  than  that
eported  by  Sanchez-Alvarez  et  al.15 where  the  unit  cost
as  estimated  at  $98.59  USD;  however,  they  did  not  include
ndirect  costs  related  to  blood  product  transfusion.  Compar-
ng  these  results,  we  found  a  difference  of  $19.63  USD  per
nit  with  regard  to  that  reported  by  Sanchez-Alvarez  et  al.15
hile  when  compared  with  reports  in  the  literature,  the  dif-
erence  between  the  two  was  $39.46  USD,  with  respect  to
he  minimum  reported.
In  our  hospital,  during  2014,  the  total  number  of  trans-
usions  of  blood  products  was  22,808.  By  applying  the
nnualized  cost  per  unit  and  extrapolating  the  percentage
f  inadequate  indications  of  this  study,  we  found  a  total  of
0,902  units  transfused  with  inadequate  indication  repre-
enting  an  estimated  cost  of  $860,766.64  USD.  Projecting
he  results  of  this  study  into  national  ﬁgures,  1,951,283  units
f  transfused  blood  products  were  inadequately  indicated,
quivalent  to  $154,063,411.85  USD.
Pereira23 in  2006  established  a  mean  of  $8.66  millionPlease  cite  this  article  in  press  as:  Cázares-Benito  MA,  et  al.  I
transfusion.  Medicina  Universitaria.  2016.  http://dx.doi.org/1
SD  as  an  annual  production  cost  in  a  sample  of  blood
anks  in  the  United  States.  If  the  percentage  of  inadequate
ndications  obtained  in  this  study  were  applied,  this  would
e  equivalent  to  a  total  cost  of  $4,139,480  USD.  However,
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ecent  studies  have  reported  annual  production  costs  of
lood  products  that  vary  from  $1.62  million  USD22 to  $72
illion  USD24; therefore,  the  cost  of  inadequate  indications
f  blood  products  could  easily  reach  $34,416,000  USD.  This
enotes  the  high  economic  impact  that  inadequate  indica-
ions  of  transfused  blood  product  units  have  on  costs  related
o  transfusion.
The  results  of  this  study  demonstrate  the  direct  relation-
hip  between  inadequate  indication  of  blood  products  and
ncreased  costs  related  to  transfusion.  In  the  future,  it  is
mportant  to  encourage  adherence  to  transfusion  guidelines
or  blood  products,  training  medical  personnel  involved  in
ransfusion,  and  making  them  aware  of  the  expense  involved
n  inadequate  indication  of  blood  products  in  each  of  the
reas  of  the  hospital.  For  this,  a  transfusion  committee
hould  play  a  key  role  in  the  development  and  maintenance
f  guidelines.
Parallel  to  this  study,  Alvarado-Navarro  conducted
esearch  related  to  medical  knowledge  of  transfusion  in
hysicians  from  our  hospital  involved  in  the  use  of  this
herapeutic  resource.  Their  results  support  the  need  to
mplement  educational  programs,25 which  in  the  long-term
ould  signiﬁcantly  affect  costs  related  to  blood  transfusion.
This  study  did  not  include  transfusions  of  blood  prod-
cts  in  pediatric  patients  due  to  differing  criteria  for  their
ndication  compared  to  adults.  Cryoprecipitate  and  platelet
pheresis  were  also  excluded  because  of  the  speciﬁc  con-
itions  required  for  transfusion.  Limited  access  to  medical
ecords  and,  in  some  cases,  lack  of  data  regarding  the
mount  of  acute  bleeding  during  procedures,  could  have
nﬂuenced  the  assessment  of  transfusions,  especially  during
urgery.
The  fact  that  this  hospital  is  a  teaching  institution,  in
hich  physicians  in  training  are  admitted  every  year,  can
ead  to  changes  in  criteria  for  indicating  blood  products,
aking  it  difﬁcult  to  establish  a  standardized  transfusion
ractice.  Transfusion  medicine  courses  for  these  residents
ave  the  potential  to  greatly  improve  every  day  practice.
Regarding  cost  analysis,  this  study  included  only  costs
irectly  related  with  processing  units  of  blood  products,
ithout  taking  into  account  indirect  costs  (labor,  equipment
epreciation,  maintenance  costs  of  facilities,  etc.)  or  annual
uctuation,  which  could  increase  unit  processing  costs.
In  conclusion,  this  report  shows  that,  based  on  the  guide-
ines  of  the  AABB,  almost  half  of  the  transfusions  were
nadequately  indicated,  involving  an  estimated  unnecessary
ost  over  $860,000  USD  for  a  total  of  10,902  units.  Transfu-
ion  of  blood  products  has  a  considerable  economic  impact
or  hospitals;  therefore,  it  is  necessary  to  implement  guide-
ines  to  justify  the  use  of  blood  products  as  well  as  perform
eriodic  audits  where  transfusion  committees  play  a  promi-
ent  role.
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